<DOC>
	<DOCNO>NCT00002456</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . Sometimes transplanted cell make immune response normal tissue . Methotrexate cyclosporine may prevent happen . PURPOSE : Phase III trial study effectiveness treatment methotrexate cyclosporine bone marrow transplantation provide protection acute graft-versus-host disease .</brief_summary>
	<brief_title>Graft-Versus-Host Disease Prevention Treating Patients Who Are Undergoing Bone Marrow Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy combination methotrexate cyclosporine , administer grafting , prevent development acute graft versus host disease ( GVHD ) patient undergo allogeneic bone marrow transplantation . OUTLINE : Patients receive methotrexate IV day 1,3,6 , 11 . Patients also receive cyclosporine IV twice day patient eating , administer orally twice day . Cyclosporine begin day -1 continue day 180 . The dose reduce begin day 50 . PROJECTED ACCRUAL : Accrual continue notice .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Ongoing bone marrow transplantation HLAmatched sibling HLA nonidentical family member unrelated donor PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not severely limited disease leukemia Hematopoietic : Not specify Hepatic : No severe hepatic disease Renal : No history hemorrhagic cystitis No renal disease Cardiovascular No symptomatic cardiac disease Other : No contraindication use cyclosporine methotrexate PRIOR CONCURRENT THERAPY : No concurrent experimental treatment GVHD prophylaxis study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood non-Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult non-Hodgkin lymphoma</keyword>
	<keyword>graft versus host disease</keyword>
</DOC>